Canaccord Genuity Maintains Hold on Moderna, Raises Price Target to $106
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Bill Maughan maintains a Hold rating on Moderna (MRNA) and raises the price target from $91 to $106.
May 03, 2024 | 9:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Hold rating on Moderna but raises the price target from $91 to $106.
The increase in price target by Canaccord Genuity suggests a positive outlook on Moderna's stock value in the short term, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100